TipRanks

Orbimed Advisors Llc Insider Profile

53 Followers
Orbimed Advisors Llc, Director, Ten Percent Owner at ADARx Pharmaceuticals, holds 588.24K shares in ADARx Pharmaceuticals (Ticker: ADRX), holds 1.76M shares in Electra Therapeutics Inc. (Ticker: ETRA), holds 2.71M shares in BlossomHill Therapeutics, Inc. (Ticker: BLSM).
tipranks
Orbimed Advisors Llc

Orbimed Advisors Llc
ADARx Pharmaceuticals (ADRX)
Director, Ten Percent Owner

Ranked #1,670 out of 109,287 Corporate Insiders

Profitable Transactions

57%
138 out of 242 Profitable Transactions

Average Return

+9.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$2B
17.77%
15.31%
14.15%
8.87%
43.89% Others
A breakdown of Orbimed Advisors Llc's holdings

Insider Roles

Enliven Therapeutics
(ELVN)
Ten Percent Owner
Rhythm Pharmaceuticals
(RYTM)
See Remarks, Ten Percent Owner
Insulet
(PODD)
Director
Spyre Therapeutics
(SYRE)
Ten Percent Owner
+50 other positions
Roles that Orbimed Advisors Llc holds in companies

Most Profitable Insider Trade

Stock:
Shattuck Labs
(STTK)
Rating:Informative Buy
Date:Sep 02, 2025 - Sep 02, 2026
Return:+584.10%
The most profitable trade made by Orbimed Advisors Llc

Orbimed Advisors Llc's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ADARx Pharmaceuticals
Sep 30, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$10.56M
ICPT
Intercept Pharma
Jul 21, 2015
―
Uninformative Buy
―
$21.29M
Adaptimmune Therapeutics
Jun 06, 2018
Director
Informative Sell
253.63K
$137.24K
Viewray
Aug 20, 2018
Ten Percent Owner
Informative Sell
5.19M
―
Glaukos
Mar 06, 2018
Director
Informative Sell
26.79M
$0.00
STDY
Steadymed
Sep 07, 2018
―
Informative Sell
18.94M
$0.00
Nabriva Therapeutics
Dec 30, 2016
Director, Ten Percent Owner
Informative Buy
―
$3.92K
Spyre Therapeutics
Feb 21, 2017
Ten Percent Owner
Informative Buy
563.88K
$146.59M
CTIC
CTI BioPharma
Jan 11, 2021
―
Informative Sell
7.00M
$68.36M
X4 Pharmaceuticals
Nov 20, 2017
Ten Percent Owner
Informative Buy
3.66M
$6.26M
SCPH
scPharmaceuticals
Aug 15, 2024
―
Informative Buy
2.00M
$1.43M
Palvella Therapeutics
May 02, 2018
See Remarks, Ten Percent Owner
Informative Sell
6.35M
$5.73M
KALA BIO
Feb 12, 2018
Ten Percent Owner
Informative Buy
323.25K
$617.16K
Synlogic
Apr 22, 2021
Director
Uninformative Buy
5.00M
$3.73M
ARMO
Armo Biosciences Inc
Jun 22, 2018
―
Uninformative Sell
205.95M
$205.86M
Adicet Bio
Apr 09, 2026
Ten Percent Owner
Informative Sell
674.85K
$3.52M
~BOLD
Audentes Therapeutics
Mar 12, 2018
―
Informative Sell
5.47M
$212.29M
Corvus Pharmaceuticals
Jul 01, 2025
Director, Ten Percent Owner
Uninformative Sell
4.88M
$75.38M
Rhythm Pharmaceuticals
May 24, 2018
See Remarks, Ten Percent Owner
Informative Sell
595.77K
$252.92M
Whitehawk Therapeutics
Jul 02, 2018
Director, Ten Percent Owner
Informative Buy
2.99M
$17.97M
CNST
Constellation Pharmaceuticals
Jul 24, 2018
―
Uninformative Buy
―
$14.21M
Xtant Medical Holdings
Apr 14, 2025
Ten Percent Owner
Informative Sell
30.71M
$0.00
PRNB
Principia Biopharma
May 22, 2019
―
Informative Sell
30.25M
$160.65M
Guardant Health
Oct 11, 2018
Ten Percent Owner
Uninformative Buy
―
$1.64M
~LOGC
Logicbio Therapeutics
Oct 25, 2018
―
Informative Buy
11.90M
$13.39M
Inspire Medical Systems
Aug 19, 2020
Director
Informative Sell
14.93M
$126.61K
~THOR
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$337.59M
Alector
Apr 16, 2020
Ten Percent Owner
Informative Sell
2.01M
$4.29M
~AVDR
Avedro
Feb 19, 2019
―
Uninformative Buy
―
$97.48M
TCDAQ
Tricida
Nov 25, 2022
―
Informative Sell
2.21M
$0.00
TPTX
Turning Point Therapeutics
Apr 24, 2019
―
Informative Buy
6.48M
$154.11M
NextCure
May 13, 2019
Director, Ten Percent Owner
Informative Buy
5.25M
$17.19M
TELA Bio
Jul 02, 2024
Ten Percent Owner
Informative Sell
2.02M
$2.35M
ETNB
89bio
Jan 27, 2022
―
Informative Sell
592.38K
$27.15M
SWTX
Springworks Therapeutics
Sep 14, 2022
―
Informative Sell
4.92M
$263.14M
PRVL
Prevail Therapeutics
Jun 26, 2019
―
Informative Buy
15.00M
$317.92M
ALPN
Alpine Immune Sciences
May 20, 2024
―
Uninformative Sell
―
$0.00
SRRA
Sierra Oncology
Jul 01, 2022
―
Uninformative Sell
108.06M
$0.00
Arcutis Biotherapeutics
Jun 28, 2022
Ten Percent Owner
Informative Sell
7.29M
$13.06M
Passage Bio
Jun 26, 2025
Ten Percent Owner
Informative Sell
197.24K
$20.20M
Enliven Therapeutics
Jun 24, 2026
Ten Percent Owner
Informative Sell
39.01M
$293.54M
Keros Therapeutics
Dec 18, 2025
Director
Uninformative Sell
3.81M
$523.11K
Oric Pharmaceuticals
Mar 31, 2021
Director
Uninformative Sell
2.43M
$20.58M
RPTX
Repare Therapeutics
Sep 08, 2021
―
Uninformative Sell
274.79K
$8.67M
Acutus Medical
Jul 21, 2021
Director, Ten Percent Owner
Informative Buy
15.00M
―
CalciMedica
Sep 29, 2020
Ten Percent Owner
Informative Buy
9.00M
$6.91M
PMV Pharmaceuticals
Oct 27, 2025
Ten Percent Owner
Informative Sell
1.52M
$6.87M
Prelude Therapeutics
Apr 23, 2026
Director, Ten Percent Owner
Informative Buy
12.50M
$6.84M
Damora Therapeutics
Aug 17, 2023
Ten Percent Owner
Informative Sell
617.01K
$32.64M
KNTE
Kinnate Biopharma
Apr 05, 2024
―
Uninformative Sell
―
$0.00
TERN
Terns Pharmaceuticals
Jul 17, 2024
―
Informative Sell
561.64K
$40.01M
DBTX
Decibel Therapeutics
Feb 19, 2021
―
Informative Buy
30.00M
$4.34M
Edgewise Therapeutics
Apr 04, 2025
Director, Ten Percent Owner
Informative Buy
10.00M
$17.97M
ImageneBio
Jul 30, 2025
Director
Uninformative Buy
208.19K
$3.25M
NeuroPace
May 16, 2025
Ten Percent Owner
Informative Sell
2.67M
$41.87M
Janux Therapeutics Inc
Dec 30, 2021
Director
Informative Sell
820.12K
$4.17M
THRX
Theseus Pharmaceuticals
Feb 14, 2024
―
Uninformative Sell
―
$0.00
Compass Therapeutics
Apr 11, 2025
Director, Ten Percent Owner
Informative Sell
5.68M
$11.57M
THRD
Third Harmonic Bio, Inc.
Sep 21, 2022
―
Informative Buy
5.10M
$31.09M
VRNA
Verona Pharma
May 15, 2023
―
Informative Sell
9.94M
$403.88M
Disc Medicine
Mar 26, 2025
Director
Informative Sell
310.48K
$15.52M
TSBX
Turnstone Biologics Corp.
Aug 12, 2025
―
Uninformative Sell
―
$0.00
ARS Pharmaceuticals
Aug 28, 2024
Director
Informative Sell
1.09M
$30.25M
ArriVent BioPharma, Inc.
Jan 31, 2024
Director, Ten Percent Owner
Informative Buy
8.00M
$23.81M
MBX Biosciences, Inc.
Feb 19, 2025
Director, Ten Percent Owner
Informative Buy
2.02M
$40.51M
Upstream Bio, Inc.
Oct 17, 2024
Director, Ten Percent Owner
Informative Buy
14.03M
$13.57M
Traws Pharma
Apr 28, 2026
Ten Percent Owner
Informative Buy
998.21K
$431.97K
Sionna Therapeutics, Inc.
Jul 09, 2026
Director
Uninformative Sell
3.85M
$9.98M
Shattuck Labs
Sep 02, 2025
Director
Informative Buy
5.42M
$36.61M
Q32 Bio
Jun 01, 2026
Director, Ten Percent Owner
Informative Buy
15.00M
$5.66M
Scribe Therapeutics Inc.
Jul 29, 2026
Director
Uninformative Buy
―
$23.66M
Braveheart Bio, Inc.
Aug 11, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$5.95M
BlossomHill Therapeutics, Inc.
Aug 12, 2026
Director
Uninformative Buy
―
$44.68M
Electra Therapeutics Inc.
Sep 23, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$15.79M
RLYP
Relypsa Inc
Jul 26, 2016
―
Informative Sell
129.39M
$236.73M
MRTX
Mirati Therapeutics
Feb 05, 2015
―
Informative Buy
2.00M
$74.37M
SIENQ
Sientra
Oct 13, 2015
―
Informative Sell
1.72M
$427.50
Pacira Pharmaceuticals
Mar 13, 2012
Ten Percent Owner
Informative Sell
1.11M
$89.01M
Anthera Pharmaceuticals
Feb 01, 2013
Director
Informative Buy
3.76M
―
OTIC
Otonomy
Nov 30, 2015
―
Informative Sell
1.94M
$212.76K
Insulet
―
Director
―
$233.65M
NXTM
NxStage Medical
Dec 13, 2010
―
Informative Sell
53.25K
$80.71M
LOXO
Loxo Oncology
Dec 12, 2017
―
Informative Sell
20.63M
$220.82M
XLRN
Acceleron Pharma
Sep 26, 2013
―
Uninformative Buy
―
$103.12M
Supernus Pharmaceuticals
Feb 14, 2013
Ten Percent Owner
Informative Sell
2.28M
$33.56M
~CCXI
ChemoCentryx
Feb 15, 2012
―
Uninformative Buy
―
$47.23M
ALBO
Albireo Pharma
Jun 11, 2009
―
Uninformative Sell
―
$65.60M
ROKA
Sorrento Tech Inc
Oct 05, 2017
―
Informative Sell
137.10K
$19.75K
Athersys
Apr 29, 2011
Ten Percent Owner
Informative Sell
551.98K
―
Amarin
Sep 05, 2012
Director
Uninformative Sell
3.37M
$72.65K
AVNR
Avanir Pharmaceuticals
―
―
―
―
~GNOM
Complete Genomics
―
―
―
―
GIVN
Given Imaging Ltd
―
―
―
―
VOLC
Volcano Corp
―
―
―
―
~AMBI
Ambit
May 24, 2013
―
Informative Buy
233.37K
―
List of latest transactions for each holding click on a transaction to see Orbimed Advisors Llc's performance on stock

Orbimed Advisors Llc insider profile FAQ

What is the percentage of profitable transactions made by Orbimed Advisors Llc?
The percentage of profitable transactions made by Orbimed Advisors Llc is 57%.
    What is the average return per transaction made by Orbimed Advisors Llc?
    The average return per transaction made by Orbimed Advisors Llc is 9.00%.
      What stocks does Orbimed Advisors Llc hold?
      Orbimed Advisors Llc holds: ADRX, ICPT, ADAPY, VRAYQ, GKOS, STDY, NBRVF, SYRE, CTIC, XFOR, SCPH, PVLA, KALA, SYBX, ARMO, ACET, ~BOLD, CRVS, RYTM, WHWK, CNST, XTNT, PRNB, GH, ~LOGC, INSP, ~THOR, ALEC, ~AVDR, TCDAQ, TPTX, NXTC, TELA, ETNB, SWTX, PRVL, ALPN, SRRA, ARQT, PASG, ELVN, KROS, ORIC, RPTX, AFIB, CALC, PMVP, PRLD, DMRA, KNTE, TERN, DBTX, EWTX, IMA, NPCE, JANX, THRX, CMPX, THRD, VRNA, IRON, TSBX, SPRY, AVBP, MBX, UPB, TRAW, SION, STTK, QTTB, SCTX, BRVE, BLSM, ETRA, RLYP, MRTX, SIENQ, PCRX, ANTH, OTIC, PODD, NXTM, LOXO, XLRN, SUPN, ~CCXI, ALBO, ROKA, ATHXQ, AMRN, AVNR, ~GNOM, GIVN, VOLC, ~AMBI stocks.
        What was Orbimed Advisors Llc’s latest transaction?
        Orbimed Advisors Llc latest transaction was an Uninformative Buy of ―.
          What was Orbimed Advisors Llc's most profitable transaction?
          Orbimed Advisors Llc’s most profitable transaction was an Informative Buy of STTK stock on September 2, 2025. The return on the trade was 584.10%.
            What is Orbimed Advisors Llc's role in ADARx Pharmaceuticals?
            Orbimed Advisors Llc's role in ADARx Pharmaceuticals is Director, Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.